David L. Brinkley
Nessuna posizione attualmente
Profilo
David L.
Brinkley worked as a Director of New Product Planning at Pfizer Inc. and Smithkline Beckman Corp.
He was also the Head of Business Development at Innoviva, Inc. and a Director at Ziarco Pharma Ltd.
Brinkley received his graduate degree from The Johns Hopkins University and his undergraduate degree from Kent State University.
Precedenti posizioni note di David L. Brinkley
| Società | Posizione | Fine |
|---|---|---|
| ARATANA THERAPEUTICS INC | Director/Board Member | 18/07/2019 |
| INNOVIVA, INC. | Corporate Officer/Principal | 01/07/2013 |
Smithkline Beckman Corp
 Smithkline Beckman Corp Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beckman Corp is a private company that manufactures pharmaceutical products. The company is based in Philadelphia, PA. Smithkline Beckman was acquired by Smithkline Beecham Plc on July 27, 1989 for $16,082.37 million. | Corporate Officer/Principal | 01/01/1995 |
| PFIZER, INC. | Corporate Officer/Principal | - |
Ziarco Pharma Ltd.
 Ziarco Pharma Ltd. BiotechnologyHealth Technology Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom. | Director/Board Member | - |
Formazione di David L. Brinkley
| The Johns Hopkins University | Graduate Degree |
| Kent State University (Ohio) | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| INNOVIVA, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Aratana Therapeutics, Inc.
 Aratana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS. | Health Technology |
Smithkline Beckman Corp
Smithkline Beckman Corp Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beckman Corp is a private company that manufactures pharmaceutical products. The company is based in Philadelphia, PA. Smithkline Beckman was acquired by Smithkline Beecham Plc on July 27, 1989 for $16,082.37 million. | Health Technology |
Ziarco Pharma Ltd.
Ziarco Pharma Ltd. BiotechnologyHealth Technology Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- David L. Brinkley
